2025 Volume 13 Issue 1 Pages 44-49
“Post-kidney transplant thrombotic microangiopathy (TMA)” was thought to be predominantly secondary TMA triggered by such as rejection, infection, and the use of immunosuppressive drugs. However, in some cases, it developed immediately after kidney transplantation possible due to ischemia–reperfusion injury, and the condition is sudden and serious, with some cases being caused by atypical hemolytic uremic syndrome (aHUS). In June 2023, the aUHS Clinical Practice Guide was published, eight years after the previous one. In this revision, aHUS is defined as “complement-mediated TMA,” in which TMA is caused by abnormal activation of the complement system. However, in clinical practice, the reality is that diagnosis and treatment are still often difficult, and the treatment of aHUS in kidney transplants can be particularly confusing. In this article, we would like to discuss the treatment strategy for aHUS among post-kidney transplant TMA based on the new clinical guideline.
